Tirzepatide may lower blood pressure largely because of weight loss and improved metabolic function
We cover where each Phase 3 trial stands, what Eli Lilly has said publicly, how this timeline compares to semaglutide and tirzepatide approvals, and what you can do while waiting
adults currently taking GLP-1 medications for weight loss has climbed to 11% in 2026, up from 3% just two years ago
In this context, the aim of the present document is to summarize, in the form of a narrative literature review, the currently available data on the main mechanisms of action of GIP/GLP-1 co-agonists and the clinical effects of tirzepatide evaluated in various clinical trials
However, the metabolic changes they produceparticularly significant weight losscan indirectly influence menstrual regularity through well-established physiological pathways